Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
暂无分享，去创建一个
H. Scher | D. Danila | O. Ståhl | D. George | E. Yu | D. Olmos | K. Fizazi | E. Efstathiou | K. Chi | G. Mason | S. Sandhu | B. Espina | P. Francis | F. Saad | A. Lopez‐Gitlitz | P. Lara | M. Smith | K. Urtishak | Xin Zhao | M. Smith | A. Lopez-Gitlitz | K. Urtishak